Tenaya Therapeutics Publishes TN-401 Gene Therapy Preclinical Data In Nature Communications Medicine

3/18/24 8:34:06 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $TNYA alert in real time by email

TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease

Tenaya Anticipates Dosing First Patient in Phase 1b RIDGE™-1 Clinical Trial of TN-401

in Second Half of 2024

Get the next $TNYA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TNYA

Date	Price Target	Rating	Analyst
6/10/2024		Outperform	William Blair
11/30/2023	$7.00	Outperform	Leerink Partners
6/15/2022	$25.00	Buy	H.C. Wainwright
8/24/2021		Outperform	Cowen & Co.
8/24/2021	$31.00	Overweight	Morgan Stanley
8/24/2021	$37.00	Buy	Chardan Capital
8/24/2021	$40.00	Overweight	Piper Sandler

More analyst ratings

$TNYA
Press Releases

Fastest customizable press release news feed in the world

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 12,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $1.97 per share, which is equal to the closing price of Tenaya's common stock on November 15, 2024. Each stock option has a ten-year term and vests as follows over a total of fo
11/19/24 8:00:00 AM ET
$TNYA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 Data from Cohort 1 of MyPEAK-1 to be Reported in December 2024 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. "We are pleased to share meaningful progress on our lead TN-201 gene therap
11/6/24 4:05:00 PM ET
$TNYA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediatric MYBPC3-associated HCM Disease Burden SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today shared updates related to its ongoing Phase 1b/2 MyPEAK-1 clinical trial of TN-201. TN-201 is being developed
10/17/24 4:30:00 PM ET
$TNYA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$TNYA
Leadership Updates

Live Leadership Updates

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a
4/26/23 7:00:00 AM ET
$NKTX
$TNYA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. "We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercia
12/7/22 4:30:00 PM ET
$TNYA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Tenaya Therapeutics Provides 2022 Business Updates
Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC) IND applications for TN-201 and TN-301 (previously named TYA-11631) expected to be submitted in the second half of 2022 Appoints Jennifer Drimmer, J.D., as General Counsel Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic
1/10/22 8:00:00 AM ET
$EXEL
$TNYA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Tenaya Therapeutics Publishes TN-401 Gene Therapy Preclinical Data In Nature Communications Medicine

Chat with this insight

Recent Analyst Ratings for $TNYA

$TNYA SEC Filings

SEC Form 10-Q filed by Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form S-8 filed by Tenaya Therapeutics Inc.

$TNYA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

$TNYA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

William Blair initiated coverage on Tenaya Therapeutics

Leerink Partners initiated coverage on Tenaya Therapeutics with a new price target

H.C. Wainwright initiated coverage on Tenaya Therapeutics with a new price target

$TNYA Press Releases

Fastest customizable press release news feed in the world

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

$TNYA Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target

William Blair Initiates Coverage On Tenaya Therapeutics with Outperform Rating

HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target

$TNYA Leadership Updates

Live Leadership Updates

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

Tenaya Therapeutics Provides 2022 Business Updates

$TNYA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Column Group Iii Gp, Lp bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

Goeddel David V bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

$TNYA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, Accounting and Fin. Ops. Saito Chihiro sold $4,787 worth of shares (2,258 units at $2.12), decreasing direct ownership by 4% to 60,983 units (SEC Form 4)

SEC Form 4 filed by Director Walsh Jeffrey T.

SEC Form 4 filed by Director Williams R Sanders

Recent Analyst Ratings for
$TNYA

$TNYA
SEC Filings

$TNYA
Large Ownership Changes

$TNYA
Analyst Ratings

$TNYA
Press Releases

$TNYA
Market Insights

$TNYA
Leadership Updates

$TNYA
Insider Purchases

$TNYA
Insider Trading